This program has an associated Grand Rounds; Click Here for information.
For patients with cardiovascular disease, one size does not fit all.
This new CME-certified webcourse – endorsed by the National Lipid Association – examines the importance of lipoprotein management for secondary prevention of major adverse cardiac events in post-ACS patients. Participants will learn to recognize residual risk associated with even intense statin therapy to lower LDL, as well as the limitations of current therapies to increase HDL, while building an awareness of the prospects of novel therapies to increase HDL and reduce CVD risk in ACS patients, as well as to provide primary prevention in high-risk patients.
MICHAEL MILLER, MD, FACC, FAHA
Professor, Departments of Medicine, Epidemiology,
and Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Michael Miller, MD, FACC, FAHA is Professor of Medicine in the Division of Cardiology and Professor of Epidemiology and Preventive Medicine at the University of Maryland School of Medicine. He also is Director, Center for Preventive Cardiology, at the University of Maryland Medical System and Staff Physician at the Veterans Affairs Medical Center in Baltimore. His major research interests are disorders of lipid and lipoprotein metabolism, molecular studies of HDL cholesterol, triglycerides and the postprandial response to dietary fat, nontraditional coronary risk factors, and clinical trials to reduce atherosclerosis. Dr. Miller has participated in landmark clinical trials including AVERT, MIRACL, PROVE-IT, TNT and COURAGE.
He is certified by the National Board of Medical Examiners and the American Board of Internal Medicine, including certifications in internal medicine and clinical lipidology and recertification in cardiovascular disease. Dr. Miller is a Fellow of the American College of Cardiology and the American Heart Association Council on Arteriosclerosis. He is also an active member of the American Heart Association Council on Epidemiology.
Dr. Miller has authored more than 250 original articles, book chapters, and other publications. Original research articles have appeared in the BMJ, Circulation, JACC, JAMA, NEJM, PNAS and Science. He is the co-author of The Practice of Coronary Disease Prevention, published by Williams and Wilkins (1996) and the AMA Guide to Preventing and Treating Heart Disease (2008). Dr. Miller has served on the program faculty for the American College of Cardiology Self-Assessment Program (ACCSAP) and Complex Lipid Management Self-Assessment Program that involves preparation for certification in Cardiology and Clinical Lipidology, respectively, and most recently as Chair for the AHA Scientific Statement: Triglycerides and Cardiovascular Disease. Currently, he is an Associate Editor for the journal BMC Public Health, and a member of several other editorial boards.
Dr. Miller is Past President of the American Society of Preventive Cardiology. His research has been supported by the National Institutes of Health, American Heart Association, and Veteran's Affairs Administration. He received a bachelor’s degree from Rutgers College and his medical doctorate from the University of Medicine and Dentistry of New Jersey. Following a medical residency at the University of Cincinnati Hospital, he completed two fellowships at Johns Hopkins, one in lipoprotein metabolism and the second in cardiovascular disease.
This activity is intended for cardiologists and primary care physicians involved in the treatment of patients with dyslipidemia.
This activity was designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Examine the extent of residual CVD risk that continues to burden dyslipidemic ACS patients despite intensive statin treatment
- Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk
- Explain the rationale for developing CETP modulators and inhibitors to increase HDL and reduce CVD risk
- Discuss how the modulation of complex cholesterol metabolism could have an impact on atherogenesis and improve clinical outcomes
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email firstname.lastname@example.org
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
FACULTY AND STEERING COMMITTEE:
Michael Miller, MD, FACC, FAHA: Consultant: Amarin, Abbott, Roche; Research: Abbott, Merck, Roche; Speaker: Merck
Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA: Advisory Board: Abbott, Amgen, AstraZeneca, LipoScience Inc., Sanofi-Aventis; Stock Holdings: LipoScience Inc.
Eliot A. Brinton, MD, FAHA, FNLA: Consultant: Abbott, Amarin, Daiichi-Sankyo, Essentialis, GlaxoSmithKline, Merck, Roche; Speaker: Abbott, Amarin, Daiichi-Sankyo, GlaxoSmithKline, Merck; Researcher: Abbott, Amarin, Merck; Scientific Advisory Board: Atherotech
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Barry Watkins, PhD; Bradley Pine; Blair St. Amand; Jay Katz, Dana Simpler, MD: Nothing to Disclose
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.
Instructions for Participants and Obtaining CME Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.
|This program is endorsed by the National Lipid Association
|This activity is jointly sponsored by
|Supported by an independent educational grant from Genentech